Innovent Wins CHMP Support for Zybrivo in Lung Cancer
Palo Alto, California, USA, and Suzhou, China, November 15, 2026 Innovent Biologics has announced that its immunotherapy Zybrivo® (sintilimab)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Palo Alto, California, USA, and Suzhou, China, November 15, 2026 Innovent Biologics has announced that its immunotherapy Zybrivo® (sintilimab)...
Columbus, Ohio, USA, November 12, 2026 Andelyn Biosciences has announced a strategic partnership with South Korean biotechnology company Celliaz...
Aurora, Colorado, USA, November 12, 2026 University of Colorado Anschutz Medical Campus has reported important findings from a long-term...
Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 12, 2026 Novo Nordisk has announced the submission of regulatory applications...
London, United Kingdom, November 13, 2026 GSK plc has announced that its Bexsero (4CMenB) meningococcal group B vaccine has...
Stockholm, Sweden, November 13, 2026 Eisai Co., Ltd. and Biogen Inc., in collaboration with BioArctic AB, have announced the...
Milan, Italy, November 13, 2026 Bracco Group and Avicenna.AI have announced that the U.S. Food and Drug Administration (FDA)...
Tokyo, Japan, November 12, 2026 Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) in Japan for Enhertu®...
Tarrytown, New York, USA, November 12, 2026 Regeneron Pharmaceuticals, Inc. has announced encouraging Phase 2 results for baloncibart (REGN7544),...
Nashville, Tennessee, USA, November 10, 2026 Virtuoso Surgical, Inc. has received De Novo authorization from the U.S. Food and...
